Company news

Satellos Bioscience Inc news in 2026

Satellos Bioscience Inc's news releases, calls and decks from 2026, newest first.

View company

Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience

October 27, 2026

Satellos to Participate in Upcoming Investor Conferences

October 21, 2026

Satellos Granted Composition of Matter Patent for Forazapadin

October 5, 2026

Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy

September 30, 2026

Satellos Announces FDA Clearance of IND Application for Forazapadin in Facioscapulohumeral Muscular Dystrophy (FSHD) and a Partnership with FSHD Canada Foundation Providing Non-Dilutive Financing to Support Clinical Development

September 24, 2026

Satellos to Present at the 31st Annual Congress of the World Muscle Society

September 15, 2026

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

September 9, 2026

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

August 13, 2026

Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247

July 8, 2026

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

June 29, 2026

Satellos to Present Clinical Program Updates at ICNMD 2026

June 25, 2026

Satellos Bioscience Announces Results of Annual Meeting of Shareholders

June 17, 2026

Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress

May 15, 2026

Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference

April 9, 2026

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

March 27, 2026

Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

March 10, 2026

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

February 24, 2026

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

February 18, 2026

Satellos to Participate in Upcoming Investor Conferences

February 17, 2026

Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

February 12, 2026

Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

February 10, 2026

Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares

February 9, 2026

Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

February 6, 2026

Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq

February 5, 2026

Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

January 29, 2026

Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing

January 28, 2026

Decks in 2026